IN2014CN02688A - - Google Patents

Download PDF

Info

Publication number
IN2014CN02688A
IN2014CN02688A IN2688CHN2014A IN2014CN02688A IN 2014CN02688 A IN2014CN02688 A IN 2014CN02688A IN 2688CHN2014 A IN2688CHN2014 A IN 2688CHN2014A IN 2014CN02688 A IN2014CN02688 A IN 2014CN02688A
Authority
IN
India
Prior art keywords
intestinal
drug
drug conjugate
diseases
relates
Prior art date
Application number
Inventor
Michael Davidson
John F Arnett
Sadik Elshani
Roelof Rongen
Original Assignee
Davidson Lopez Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Davidson Lopez Llc filed Critical Davidson Lopez Llc
Publication of IN2014CN02688A publication Critical patent/IN2014CN02688A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to a drug conjugate including a drug and a plant steroid. The drug conjugate may target the drug for intestinal cell delivery and thus may be used to treat diseases including intestinal diseases or to affect intestinal metabolism. The invention therefore also relates to treating intestinal diseases and affecting intestinal metabolism with the drug conjugate.
IN2688CHN2014 2011-09-16 2012-09-14 IN2014CN02688A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161535661P 2011-09-16 2011-09-16
US201261675966P 2012-07-26 2012-07-26
PCT/US2012/055549 WO2013040441A1 (en) 2011-09-16 2012-09-14 Plant steroids and uses thereof

Publications (1)

Publication Number Publication Date
IN2014CN02688A true IN2014CN02688A (en) 2015-07-03

Family

ID=47883793

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2688CHN2014 IN2014CN02688A (en) 2011-09-16 2012-09-14

Country Status (15)

Country Link
US (2) US10086082B2 (en)
EP (1) EP2755660B1 (en)
JP (2) JP6035338B2 (en)
KR (1) KR20140093661A (en)
CN (2) CN103987390A (en)
AU (1) AU2012308332A1 (en)
BR (1) BR112014006222A2 (en)
CA (1) CA2848979C (en)
EA (1) EA201490637A1 (en)
HK (1) HK1200358A1 (en)
IL (1) IL231541A0 (en)
IN (1) IN2014CN02688A (en)
MX (1) MX2014003260A (en)
SG (1) SG11201400652UA (en)
WO (1) WO2013040441A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2903435A1 (en) 2013-03-08 2014-09-12 Allergan Inc. Antibiotic conjugates directly linked with steroid drugs
CA2899500A1 (en) * 2013-03-08 2014-09-12 Allergan, Inc. Cyclosporine a-steroid conjugates
US10301268B2 (en) 2014-03-13 2019-05-28 The Salk Institute For Biological Studies Analogs of fexaramine and methods of making and using
US10077268B2 (en) 2014-03-13 2018-09-18 Salk Institute For Biological Studies FXR agonists and methods for making and using
US10238664B2 (en) 2014-07-09 2019-03-26 Duke University Compositions and methods for the repair of myelin
US11458146B2 (en) 2017-01-13 2022-10-04 Duke University Compositions and methods for the treatment of myelin related and inflammation related diseases or disorders
KR102139678B1 (en) * 2017-11-24 2020-07-31 전북대학교 산학협력단 A Composition for Treating Atopy or Pruritus Comprising N-acetyl or N-acyl amino acid
CN110051674A (en) * 2018-07-26 2019-07-26 中国人民解放军空军军医大学第一附属医院 Purposes of the stigmasterol in the drug of preparation treatment gastric cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000052029A1 (en) * 1999-03-04 2000-09-08 Eugene Science Inc. Water-soluble sterol derivative for inhibiting cholesterol absorption and process for preparing the same
WO2001000653A1 (en) * 1999-06-23 2001-01-04 Forbes Medi-Tech Inc. Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
AU2002252387A1 (en) * 2001-03-14 2002-09-24 Lipogenics, Inc. Novel anti-inflammatory compositions and methods of use
JP4084199B2 (en) 2001-05-09 2008-04-30 メディプレックス コーポレーション Process for increasing mucosal absorption of amphiphilic heparin derivatives
SE0103765D0 (en) * 2001-11-09 2001-11-09 Astrazeneca Ab New use
US20040236125A1 (en) * 2002-09-25 2004-11-25 Forbes Medi-Tech Inc. Novel structures and compositions comprising sterols and/or stanols and specific classes of anti-inflammatory agents and use thereof in treating or preventing cardiovascular disease, its underlying conditions including hyperlipidemia and other disorders having inflammation as part of their aetiology or presentation
WO2004095926A2 (en) 2003-04-28 2004-11-11 Monsanto Technology, Llc Treatment of plants and plant propagation materials with an antioxidant to improve plant health and/or yield
US20050234025A1 (en) * 2004-04-20 2005-10-20 Forbes Medi-Tech Inc. Compositions comprising one or more policosanols and/or policosanoic acids combined with sterol and/or steroid based ascorbic acid derivatives, and uses thereof
US20090110633A1 (en) * 2005-03-14 2009-04-30 Shiladitya Sengupta Nanocells for Diagnosis and Treatment of Diseases and Disorders
WO2008036841A2 (en) 2006-09-22 2008-03-27 Dharmacon, Inc. Tripartite oligonucleotide complexes and methods for gene silencing by rna interference
WO2008058156A2 (en) * 2006-11-06 2008-05-15 Jina Pharmaceuticals Inc. Guggulphospholipid methods and compositions
US8188060B2 (en) * 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
US20120029078A1 (en) 2010-03-02 2012-02-02 Imagenetix, Inc. Compositions comprising myristic acid and uses thereof

Also Published As

Publication number Publication date
US20150141390A1 (en) 2015-05-21
AU2012308332A1 (en) 2014-04-10
MX2014003260A (en) 2014-09-08
CA2848979A1 (en) 2013-03-21
SG11201400652UA (en) 2014-09-26
BR112014006222A2 (en) 2017-04-11
EP2755660B1 (en) 2019-11-06
CN103987390A (en) 2014-08-13
EP2755660A4 (en) 2015-03-18
JP6035338B2 (en) 2016-11-30
US20190083632A1 (en) 2019-03-21
HK1200358A1 (en) 2015-08-07
JP2014526515A (en) 2014-10-06
KR20140093661A (en) 2014-07-28
WO2013040441A1 (en) 2013-03-21
US10086082B2 (en) 2018-10-02
JP2017019871A (en) 2017-01-26
EP2755660A1 (en) 2014-07-23
CN109384825A (en) 2019-02-26
CA2848979C (en) 2019-11-05
EA201490637A1 (en) 2014-11-28
IL231541A0 (en) 2014-04-30

Similar Documents

Publication Publication Date Title
IN2014CN02688A (en)
PH12019502292A1 (en) Methods and compositions for treatment of a genetic condition
TN2018000094A1 (en) Compositions and methods for inhibiting gene expression of lpa
AU2012205878A8 (en) miRNA for treating diseases and conditions associated with neo-angiogenesis
MX2013008851A (en) Compostions and methods for treating chronic inflammation and inflammatory diseases.
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
MX348003B (en) Methods and means to modify a plant genome.
MY177912A (en) Vegf neutralizing prodrugs for the treatment of ocular conditions
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
ZA201107215B (en) Therapeutic agents for the treatment of diseases associated with undersired cell proliferation
NZ700399A (en) Boronic acid conjugates of oligonucleotide analogues
PH12016500863A1 (en) Tetracyclic autotaxin inhibitors
WO2010085665A3 (en) Targeted delivery system
GB2497453B8 (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
MX2013013649A (en) Quinone compounds for treating ape1 mediated diseases.
MX367926B (en) Pharmaceutical composition for a sustained release of lanreotide.
MX356317B (en) Treatment of symptoms associated with female gastroparesis.
EP3377622A4 (en) Targeted delivery of therapeutic proteins bioencapsulated in plant cells to cell types of interest for the treatment of disease
GB201022049D0 (en) Methods
WO2010117727A3 (en) Phenserine and posiphen for treating neuropsychiatric and neurodegenerative conditions
EP2564849A4 (en) Prophylactic or therapeutic agent for diseases associated with pains in urinary organs
MX352788B (en) Treatment of vaginal atrophy as novel indication for myrrh.
MX350868B (en) MEDICAMENTS and METHODS FOR TREATING CANCER.
UA100661U (en) Method for increasing efficacy of treatment of non-calculous cholecystitis in the setting of metabolic syndrome
UA65038U (en) method for treatment of patients with tocomanias